Background β-catenin plays a key role in the progression of colorectal cancer (CRC). However, its prognostic significance for patients with CRC remains controversial. Methodology Identical search strategies were used to search relevant literatures in the PubMed, Embase and Web of Science databases. The correlation between β-catenin expression and clinicopathological features and prognosis was analyzed. Principal Findings A total of 18 studies met the inclusion criteria, which comprised 3665 cases. Meta-analysis suggested that β-catenin overexpression in the nucleus was significantly associated with disease free survival (DFS) (n = 541 in 3 studies; HR = 1.87, 95% CI: 1.28–2.71; Z = 3.26; P = 0.001) and overall survival (OS) for CRC patients (n = 2630 in 10 studies; HR = 1.55, 95% CI: 1.12–2.14; Z = 2.62; P = 0.009). However, there was no significant association between β-catenin expression in the cytoplasm and OS (n = 1327 in 3 studies; HR = 1.04, 95% CI: 0.88–1.24, Z = 0.46, P = 0.643). The combined odds ratio (OR) of β-catenin in the nucleus indicated that β-catenin overexpression was associated with advanced stage CRC (n = 950 in 7 studies; OR = 0.71, 95% CI: 0.53–0.94; Z = 2.35; P = 0.019) and metastasis of CRC (n = 628 in 5 studies; OR = 0.49, 95% CI: 0.25–0.96, Z = 2.06, P = 0.039). β-catenin overexpression in the nucleus had no correlation with the tumor site (colon or rectum), differentiation grade, lymph node status or depth of invasion. The pooled ORs were 1.09 (95% CI: 0.41–2.91, Z = 0.18, P = 0.856), 1.27(95% CI: 0.76–2.10, Z = 0.92, P = 0.357), 0.71(95% CI: 0.46–1.09, Z = 1.58, P = 0.115) and 0.82(95% CI: 0.4–1.68, Z = 0.53, P = 0.594). Conclusions This study showed that β-catenin overexpression in the nucleus, rather than in the cytoplasm, appeared to be associated with progress disease and a worse prognosis for CRC patients.
Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, et al. (2006) Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology 24: 386–393.
Andras C, Toth L, Molnar C, Tanyi M, Csiki Z, et al. (2012) Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3n0 colorectal adenocarcinomas: a single center retrospective study on 100 cases. Hepato-Gastroenterology 59: 1091–1097.
Toth L, Andras C, Molnar C, Tanyi M, Csiki Z, et al. (2012) Investigation of beta-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer? Pathology Oncology Research 18: 429–437.
Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, et al. (2011) Prognostic significance of Wnt-1, beta-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathology Oncology Research 17: 955–963.
Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, et al. (2011) Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 305: 1685–1694.
Matsuoka T, Mitomi H, Fukui N, Kanazawa H, Saito T, et al. (2011) Cluster analysis of claudin-1 and -4, E-cadherin, and beta-catenin expression in colorectal cancers. Journal of Surgical Oncology 103: 674–686.
Pancione M, Forte N, Fucci A, Sabatino L, Febbraro A, et al. (2010) Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Human Pathology 41: 867–876.
Magnusson C, Mezhybovska M, Lorinc E, Fernebro E, Nilbert M, et al. (2010) Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. European Journal of Cancer 46: 826–835.
Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, et al. (2009) Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Human Pathology 40: 714–725.
Bravou V, Klironomos G, Papadaki E, Taraviras S, Varakis J (2006) ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. Journal of Pathology 208: 91–99.
Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, et al. (2004) Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. International Journal of Cancer 111: 921–928.
Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, et al. (2001) Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clinical Cancer Research 7: 4013–4020.